Evidence map›Paper›PMID 35765278›Full record

ArticleOncology letters2022

Evaluating the burden of the COVID-19 pandemic on patients with colorectal cancer.

Junpei Takashima, Hirotoshi Kobayashi, Yuta Suzuki, Ayaka Koizumi, Fumi Shigehara, Kenji Yamazaki, Daisuke Fujimoto, Fumihiko Miura, Keizo Taniguchi

Open access · diamondAbstract read
In one paragraph

Article in Oncology letters, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Junpei TakashimaDepartment of Surgery, Mizonokuchi Hospital, Teikyo University School of Medicine, Kawasaki, Kanagawa 213-8507, Japan.
Hirotoshi KobayashiDepartment of Surgery, Mizonokuchi Hospital, Teikyo University School of Medicine, Kawasaki, Kanagawa 213-8507, Japan.
Yuta SuzukiDepartment of Surgery, Mizonokuchi Hospital, Teikyo University School of Medicine, Kawasaki, Kanagawa 213-8507, Japan.
Ayaka KoizumiDepartment of Surgery, Mizonokuchi Hospital, Teikyo University School of Medicine, Kawasaki, Kanagawa 213-8507, Japan.
Fumi ShigeharaDepartment of Surgery, Mizonokuchi Hospital, Teikyo University School of Medicine, Kawasaki, Kanagawa 213-8507, Japan.
Kenji YamazakiDepartment of Surgery, Mizonokuchi Hospital, Teikyo University School of Medicine, Kawasaki, Kanagawa 213-8507, Japan.
Daisuke FujimotoDepartment of Surgery, Mizonokuchi Hospital, Teikyo University School of Medicine, Kawasaki, Kanagawa 213-8507, Japan.
Fumihiko MiuraDepartment of Surgery, Mizonokuchi Hospital, Teikyo University School of Medicine, Kawasaki, Kanagawa 213-8507, Japan.
Keizo TaniguchiDepartment of Surgery, Mizonokuchi Hospital, Teikyo University School of Medicine, Kawasaki, Kanagawa 213-8507, Japan.
Teikyo University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

After the emergence of the coronavirus disease 2019 (COVID-19) pandemic, individuals needing medical help preferred to not go to the hospital to avoid the risk of severe acute respiratory syndrome coronavirus 2 infection. The present study investigated the influence of the COVID-19 pandemic on patients with colorectal cancer. Patients with colorectal cancer treated between January and December 2019 were classified as the pre-pandemic group (pre-group) and those treated between April 2020 and March 2021 as the post-pandemic group (pandemic group). The clinicopathologic features of patients who underwent surgery for colorectal cancer in the two groups were retrospectively compared. A total of 161 patients were enrolled: 79 In the pre-group and 82 in the pandemic group. Although no significant differences were observed in tumor location and surgical procedure between the two groups, circumferential lesions (P<0.001), colorectal stenting (P=0.016) and Stage IV classification (P=0.019) had a higher frequency in the pandemic group compared with the pre-group; additionally, surgical curability was significantly lower (P=0.036) in the pandemic group. The spread of COVID-19 has increased the incidence of patients with advanced colorectal cancer. To reduce this incidence, healthcare professionals should inform the general public not only about the risk of COVID-19, but also about the increased incidence of advanced colorectal cancer after the pandemic.

Indexed as

colorectal cancercoronavirus disease 2019pandemicsevere acute respiratory syndrome coronavirus 2

Identifiers

PMID35765278
PMCPMC9219025
OpenAlexW4282984154

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.